An estimated 1 in 13 children has a food allergy, which translates to an average of two children in every classroom. According to a 2024 study published in the journal Cureus, 20%-25% of children experience their first anaphylactic reaction in school. Since they have no prior history, they have not been prescribed epinephrine, the only drug that can halt and reverse the progression of life-threatening anaphylaxis.
That’s why it’s imperative for schools to have “stock” epinephrine on hand, i.e., epinephrine that’s readily available for use in an anaphylactic emergency, with or without a prior prescription.
In January, ARS Pharma, the maker of neffy® brand needle-free epinephrine nasal spray, announced the launch of their neffyinSchools program. Under the program, all public and private K-12 Schools in the US are eligible to receive two cartons (four single-use doses) of neffy, and will be eligible to receive additional free doses each time the product is used or expires. (Note that schools will only receive neffy in accordance with all applicable laws.)
As the end of the school year approaches, now is the time to meet with your child’s school nurse or principal to ensure that stock epinephrine will be available for the coming school year.
To learn more about the neffyinSchools program, visit https://www.neffy.com/community-programs/.
